Jeanne M. Palmer, MD - The Modern Management of Myelofibrosis: Practical Perspectives Surrounding the Use of JAK Inhibitors and Novel Therapeutics in the Peri-Transplant Setting

Go online to PeerView.com/BJB860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. The past decade has seen new insights into the
cytogenetics, molecular genetics, and disease biology of
myelofibrosis (MF), including the approval of first- and
second-generation JAK inhibitors and newer evidence on using JAK
inhibitors in conjunction with hematopoietic stem cell
transplantation (HCT). How can all of these advances be employed in
an effective and safe way—and lead to improved outcomes in MF?
Based on a recent PeerView Live CaseBook event, this activity will
answer that question and offer an expert-led review of the latest
efficacy, safety, and tolerability data associated with JAKi-based
therapy and the role of HCT in patient treatment. This program also
features case-based illustrations of therapy selection and
sequencing designed to highlight the key take-homes of the MF
lecture segments. Upon completion of this activity, participants
should be better able to: Assess patient- and disease-related
features that inform the diagnosis, risk assessment, and treatment
of myelofibrosis (MF), Analyze the current therapeutic roles of JAK
inhibitors and other emerging therapies in the peri-transplant
setting for managing patients with MF, Apply current data on the
safety, efficacy, and tolerability of JAK inhibitors and other
emerging therapeutic options for treating transplant-eligible
patients with MF, Develop treatment plans that incorporate first-
and second-generation JAK inhibitors for managing patients with MF,
including those who are eligible for allogeneic HSCT or as
sequential options in the non-HSCT setting.